PL2590993T3 - Polipeptydy - Google Patents

Polipeptydy

Info

Publication number
PL2590993T3
PL2590993T3 PL11743207T PL11743207T PL2590993T3 PL 2590993 T3 PL2590993 T3 PL 2590993T3 PL 11743207 T PL11743207 T PL 11743207T PL 11743207 T PL11743207 T PL 11743207T PL 2590993 T3 PL2590993 T3 PL 2590993T3
Authority
PL
Poland
Prior art keywords
polypeptides
Prior art date
Application number
PL11743207T
Other languages
English (en)
Inventor
Caroline Ekblad
Lars Abrahmsén
Original Assignee
Affibody Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody Ab filed Critical Affibody Ab
Publication of PL2590993T3 publication Critical patent/PL2590993T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL11743207T 2010-07-09 2011-07-08 Polipeptydy PL2590993T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39928510P 2010-07-09 2010-07-09
US40356110P 2010-09-17 2010-09-17
PCT/EP2011/061623 WO2012004384A2 (en) 2010-07-09 2011-07-08 Polypeptides
EP20110743207 EP2590993B1 (en) 2010-07-09 2011-07-08 Polypeptides

Publications (1)

Publication Number Publication Date
PL2590993T3 true PL2590993T3 (pl) 2015-10-30

Family

ID=44630120

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15165722T PL2933262T3 (pl) 2010-07-09 2011-07-08 Polipeptydy
PL11743207T PL2590993T3 (pl) 2010-07-09 2011-07-08 Polipeptydy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15165722T PL2933262T3 (pl) 2010-07-09 2011-07-08 Polipeptydy

Country Status (22)

Country Link
US (3) US9211344B2 (pl)
EP (2) EP2590993B1 (pl)
JP (2) JP5827994B2 (pl)
KR (1) KR101884654B1 (pl)
CN (3) CN110437320B (pl)
AU (1) AU2011275766B2 (pl)
BR (1) BR112013000452A2 (pl)
CA (1) CA2804002C (pl)
DK (2) DK2590993T3 (pl)
ES (2) ES2676403T3 (pl)
HK (2) HK1182719A1 (pl)
IL (1) IL223989B (pl)
LT (1) LT2933262T (pl)
MX (1) MX2013000314A (pl)
MY (1) MY161679A (pl)
NO (1) NO2933262T3 (pl)
NZ (1) NZ604805A (pl)
PL (2) PL2933262T3 (pl)
RU (1) RU2577964C2 (pl)
TR (1) TR201809437T4 (pl)
WO (1) WO2012004384A2 (pl)
ZA (1) ZA201300994B (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120165650A1 (en) * 2010-12-22 2012-06-28 General Electric Company Her2 binders
NZ604805A (en) 2010-07-09 2014-09-26 Affibody Ab Polypeptides
EP2621515B1 (en) 2010-09-28 2017-03-29 Aegerion Pharmaceuticals, Inc. A chimeric seal-human leptin polypeptide with increased solubility
JP6145088B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス,インコーポレーテッド 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
CN103957926B (zh) * 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
EP2729481B1 (en) 2011-07-08 2018-10-17 Amylin Pharmaceuticals, LLC Engineered polypeptides having enhanced duration of action with reduced immunogenicity
PT2817329T (pt) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polipeptioos que se ligam ao complemento humano c5
JP2020033372A (ja) * 2012-03-28 2020-03-05 アフィボディ・アーベー 経口投与
US20160009767A9 (en) * 2012-03-28 2016-01-14 Affibody Ab Oral administration
CN111763247B (zh) * 2012-09-25 2024-09-13 阿菲博迪公司 白蛋白结合多肽
US9745350B2 (en) 2012-10-05 2017-08-29 Affibody Ab HER3 binding polypeptides
ES2674983T3 (es) 2012-10-25 2018-07-05 Affibody Ab Método para la separación de proteínas que contienen un dominio que se une a albúmina
CN104854127B (zh) 2012-10-25 2020-12-25 阿菲博迪公司 白蛋白结合多肽
WO2014076177A1 (en) * 2012-11-14 2014-05-22 Affibody Ab New polypeptide
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
WO2014096163A1 (en) * 2012-12-19 2014-06-26 Affibody Ab New polypeptides
AU2014230460B2 (en) 2013-03-14 2018-04-05 Pieris Pharmaceuticals Gmbh Novel binding proteins for PCSK9
BR112015021730A2 (pt) * 2013-03-15 2017-08-29 Affibody Ab POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO OU CONJUGADO, POLINUCLEOTÍDEO QUE CODIFICA UM POLIPEPTÍDEO, COMPOSIÇÃO, POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO OU CONJUGADO E POLIPEPTÍDEO DE LIGAÇÃO AO FcRn, PROTEÍNA DE FUSÃO, CONJUGADO OU COMPOSIÇÃO PARA USO
BR112015026122A8 (pt) 2013-04-18 2020-01-21 Armo Biosciences Inc agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
BR122023020080A2 (pt) * 2013-08-28 2023-12-26 Swedish Orphan Biovitrum Ab (Publ) Ligação de polipeptídeos estáveis ao c5 do complemento humano
CA2920005C (en) 2013-08-28 2023-11-28 Affibody Ab Binding polypeptides having a mutated scaffold
US10010588B2 (en) 2013-08-30 2018-07-03 Armo Biosciences, Inc. Methods of using pegylated interleukin-10 for treating hyperlipidemia
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EP3083675B1 (en) * 2013-12-20 2018-03-07 Affibody AB Engineered albumin binding polypeptide
WO2015177175A2 (en) 2014-05-22 2015-11-26 Pieris Ag Novel specific-binding polypeptides and uses thereof
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
WO2016054101A1 (en) 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2016060996A2 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
WO2016064817A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
PL3245224T3 (pl) 2015-01-12 2021-01-25 Affibody Ab Polipeptydy wiążące il-17a
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
KR102427117B1 (ko) * 2015-04-02 2022-07-29 몰리큘라 파트너스 아게 혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
EP3665202A1 (en) 2017-08-09 2020-06-17 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
CN108362873B (zh) * 2018-02-13 2021-06-01 苏州仁端生物医药科技有限公司 一种镉离子检测试剂盒及其应用
WO2019175176A1 (en) 2018-03-13 2019-09-19 Affibody Ab Polypeptides based on a novel scaffold
CA3150442A1 (en) 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
US20220389066A1 (en) 2019-11-05 2022-12-08 Affibody Ab Polypeptides
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
EP3878515A1 (en) 2020-03-09 2021-09-15 Hober Biotech AB Therapeutic agent targeting her2
US20240101605A1 (en) 2020-12-21 2024-03-28 Affibody Ab New polypeptide
EP4291251A1 (en) 2021-02-15 2023-12-20 Affibody AB New her2-binding polypeptide
CN113416683B (zh) * 2021-06-01 2023-05-02 南昌大学 一种大肠杆菌Nissle 1917基因工程菌及其制备方法和应用
AR128475A1 (es) 2022-02-08 2024-05-15 Affibody Ab Polipéptidos y proteínas de fusión con afinidad de unión por tslp
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6362225B1 (en) 1999-01-21 2002-03-26 George Andreakos Target therapies for treating common viral infections
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
US7288265B1 (en) 2000-10-16 2007-10-30 Lectec Corporation Treating viral infection at smallpox vaccination site
CN100374456C (zh) * 2000-12-29 2008-03-12 萨文特医药公司 用于选择性癌症治疗的特异性人抗体
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
WO2005097202A2 (en) 2004-04-06 2005-10-20 Affibody Ab Use of serum albumin binding peptides conjugates for the preparation of a medicament
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
CN101128487B (zh) * 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
US8093207B2 (en) 2005-12-09 2012-01-10 Unigene Laboratories, Inc. Fast-acting oral peptide pharmaceutical products
MX2008014910A (es) * 2006-05-24 2009-01-23 Bayer Schering Pharma Ag Anticuerpos bloqueantes de la funcion de la integrina ?5?1 humanos y humanizados de gran afinidad con inmunogenicidad reducida.
WO2008021088A2 (en) 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
CA2666511A1 (en) 2006-10-11 2008-04-17 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and uses thereof
CN104710518A (zh) * 2007-07-31 2015-06-17 阿菲博迪公司 新白蛋白结合组合物、方法及应用
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
BRPI0907077A2 (pt) 2008-03-26 2016-07-26 Oramed Ltd métodos e composições para administração oral de proteínas
CN101294178A (zh) 2008-05-26 2008-10-29 江南大学 一种用两阶段培养法提高发酵生产透明质酸产量的方法
CN101294187B (zh) * 2008-06-06 2013-07-31 暨南大学 一种缓释生物活性多肽的方法与应用
WO2010020978A1 (en) 2008-08-18 2010-02-25 Oramed Pharmaceuticals Ltd Methods and compositions for oral administration of proteins
WO2010054699A1 (en) * 2008-11-17 2010-05-20 Affibody Ab Conjugates of albumin binding domain
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
NZ604805A (en) 2010-07-09 2014-09-26 Affibody Ab Polypeptides
US20120027058A1 (en) 2010-07-29 2012-02-02 The Regents Of The University Of Michigan Portable, wireless multi-channel impedance analyzer
EP2621515B1 (en) 2010-09-28 2017-03-29 Aegerion Pharmaceuticals, Inc. A chimeric seal-human leptin polypeptide with increased solubility
CN103347532A (zh) 2011-02-04 2013-10-09 爱奇司治疗公司 口服可生物利用肽药物组合物及其方法
CN103957926B (zh) 2011-07-08 2018-07-03 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
US20160009767A9 (en) 2012-03-28 2016-01-14 Affibody Ab Oral administration
CN111763247B (zh) 2012-09-25 2024-09-13 阿菲博迪公司 白蛋白结合多肽
EP3083675B1 (en) 2013-12-20 2018-03-07 Affibody AB Engineered albumin binding polypeptide

Also Published As

Publication number Publication date
AU2011275766A1 (en) 2013-01-10
ES2676403T3 (es) 2018-07-19
TR201809437T4 (tr) 2018-07-23
DK2590993T3 (en) 2015-06-29
BR112013000452A2 (pt) 2020-02-11
LT2933262T (lt) 2018-07-10
HK1209761A1 (en) 2016-04-08
CN103003296A (zh) 2013-03-27
MX2013000314A (es) 2013-01-29
US20140162956A1 (en) 2014-06-12
NO2933262T3 (pl) 2018-09-29
ES2540114T3 (es) 2015-07-08
RU2577964C2 (ru) 2016-03-20
ZA201300994B (en) 2020-05-27
EP2590993A2 (en) 2013-05-15
DK2933262T3 (en) 2018-06-25
US10329331B2 (en) 2019-06-25
JP2013534421A (ja) 2013-09-05
US20190375799A1 (en) 2019-12-12
EP2933262B1 (en) 2018-05-02
US20160108095A1 (en) 2016-04-21
JP5827994B2 (ja) 2015-12-02
JP2016053047A (ja) 2016-04-14
CN110437320A (zh) 2019-11-12
CN110437320B (zh) 2023-10-20
NZ604805A (en) 2014-09-26
CA2804002C (en) 2021-07-20
MY161679A (en) 2017-05-15
EP2590993B1 (en) 2015-05-06
PL2933262T3 (pl) 2018-10-31
AU2011275766B2 (en) 2015-10-22
IL223989B (en) 2018-10-31
WO2012004384A3 (en) 2012-03-29
US9211344B2 (en) 2015-12-15
KR20130034043A (ko) 2013-04-04
KR101884654B1 (ko) 2018-08-02
HK1182719A1 (en) 2013-12-06
JP6486810B2 (ja) 2019-03-20
RU2013102953A (ru) 2014-08-20
WO2012004384A2 (en) 2012-01-12
CA2804002A1 (en) 2012-01-12
CN110437321A (zh) 2019-11-12
EP2933262A1 (en) 2015-10-21

Similar Documents

Publication Publication Date Title
HRP20191852T8 (hr) Polipeptidi
HK1209761A1 (en) Polypeptides
DK3342786T3 (en) Anti-dll3-antistof
ZA201309174B (en) Polypeptides
IL222301A0 (en) Protease-activatable pore-forming polypeptides
AP3107A (en) 5-Alkynyl-pyrimidines
EP2566479A4 (en) AZA-INDAZOLES
EP2640189A4 (en) 3-deutero-pomalidomide
DK3466977T3 (en) Anti-vla-4-antistoffer
GB201012651D0 (en) Peptides
EP2651505A4 (en) ELECTROPORATION-INDUCED ELECTROSENSIBILIZATION
EP2641891A4 (en) PKC ACTIVATOR-
GB201016494D0 (en) Polypeptide
GB201018480D0 (en) Factors
EP2627674A4 (en) EGFR BASED PEPTIDES
AU4536P (en) TB01 Tibouchina urvilleana
AU4937P (en) FlatinsulGL Myoporum insulare
AU4931P (en) FlatwaxDarkGL Chamelaucium uncinatum
AU4822P (en) FlatwaxwhiteGL Chamelaucium uncinatum
AU4932P (en) FlatwaxpinkGL Chamelaucium uncinatum
HUE047406T2 (hu) Polipeptidek
GB201003906D0 (en) Binding polypeptides
AU2010278V (en) Little Tuffy Lomandra confertifolia
GB201008108D0 (en) Helisuacer III
GB201005840D0 (en) Multi-catch pro